SCHEMBL1021855

SCHEMBL1021855

CCN(CCN(CC)S(=O)(=O)c1cccs1)c1nc(Cc2ccccc2)ns1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
ALDH1A1 P00352 6/20 0.36
SQLE Q14534 2/20 0.35
TDP1 Q9NUW8 2/20 0.34
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 2/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
GAA P10253 1/20 0.32
CNR2 P34972 1/20 0.32
MAPK1 P28482 1/20 0.32
PTGER2 P43116 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1022524 0.92 CNR2 (0.39) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1019785 0.91 NPC1 (0.35) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1019501 0.91 TAS2R14 (0.38) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1020807 0.90 SQLE (0.36) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1018654 0.90 ALDH1A1 (0.38) ALDH1A1HPGDMAPTTSHRL3MBTL1
SCHEMBL1019424 0.89 SQLE (0.36) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1019782 0.87 RAB9A (0.35) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1021265 0.87 NPC1 (0.35) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1019792 0.85 MEN1 (0.35) FNTAFNTBPGGT1BALDH1A1SQLE
SCHEMBL1021642 0.85 ALDH1A1 (0.37) FNTAFNTBPGGT1BALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP FNTA 2308/4885FNTB 2680/4885PGGT1B 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.